Chemesis International

Bringing Vertically-Integrated Cannabis to Puerto Rico and California

This Chemesis International Inc. profile is part of a paid investor education campaign.*

Overview

Chemesis International Inc. (CSE:CSI, OTCQB:CADMF,FRA:CWAA) is a vertically-integrated seed-to-sale cannabis company that operates in Puerto Rico and California, focusing on long-term growth and stability in cannabis markets across the globe. Chemesis International provides consumers with a variety of high-quality products and has exclusive agreements with a number of renowned cannabis brands, such as California Sap and Jay & Silent Bob’s Private Stash. Through its wholly-owned subsidiary, Chemesis Latin America, the company has executed on opportunities for cultivation, production and export within the Latin American market.

Chemesis International has acquired 80 percent of Natural Ventures PR LLC, a seed-to-sale medical cannabis company based in Puerto Rico. Natural Ventures has strategic partnerships with a number of leading brands in the cannabis industry, such as Dragonglass Flake and Bake. The company has recently signed up to US$10 million in purchase agreements to supply the numerous dispensaries in Puerto Rico with various cannabis products.

Natural Ventures also facilitates the sale of Viverian, a hemp-derived CBD product line that promotes healthy living and provides consumers with quick and easy consumption methods. The brand is available through an online e-commerce platform with distribution in Arizona, Nevada and Florida. Chemesis International has also partnered with First Cannabis Medical LLC to cultivate hemp with high yields of CBD in Puerto Rico for the international cannabis markets.

Chemesis International has acquired SAP Global (SAP), a California corporation licensed for both cultivation and manufacturing at its state-of-the-art facility in Cathedral City, from which Chemesis International plans to manufacture and distribute THC products for the medical and recreational markets in the golden state. SAP is a founding member of the National Cannabis Industry Association (NCIA), and it used this position to promote changes to regulations that helped evolve the current legal framework. During this time, SAP was endorsed by publications such as the Ed Rosenthal book release, Culture Magazine, Cannabis Now Magazine and High Times Magazine, among others.

SAP’s facility is able to process up to 2,000 pounds of agricultural trim, with an expected yield of 200 pounds of cannabis oil. The company expects that it will see an annual revenue of $165.3 million by year four, with a net income of $27.2 million in California, Puerto Rico and Colombia.

Chemesis International has also announced the acquisition of the California Sap brand and catalog, which includes both cannabis oil (Gramqul) and vape cartridges, which are expected to be produced at the SAP facility. California Sap has been recognized since 2012 with numerous awards across California and Nevada, including 25 gold rankings for best CO2, best topical, best product, best concentrate, best cartridge, highest terpene and more.

Chemesis International has also closed a definitive agreement acquiring Desert Zen, a fully compliant recreational and medicinal cannabis manufacturing, distribution and transportation company also located in Cathedral City. The company has a significant existing network serving farmers and dispensaries, as well as other organizations like Desert Zen.

The company has further advanced its multistate operator strategy by acquiring hemp cultivation and processing licenses in Michigan. The acquisition of the licenses was followed by gaining the state’s approval to break ground on the company’s hemp processing facility. Michigan is expected to one of the largest cannabis markets in the US and is home to the country’s second highest number of registered medical users.

As part of its brand development strategy, Chemesis International has signed a multi-year licensing agreement with Kevin Smith and Jason Mewes, also known as Jay and Silent Bob, for the development and promotion of cannabis products in the US market. Holding a collective social media presence of 12.4 million followers, Smith provides access to a large selection of potential consumers.

Chemesis International launched the Jay and Silent Bob brand in December 2018 and brought in over US$100,000 in purchase orders in the first week of sales. The company has also partnered with Dank City to help with marketing for the brand.

As part of its retail strategy, Chemesis International has acquired a 19.9 percent interest in GSRX Industries Inc. (OTCMKTS:GSRX), a company in the business of acquiring, developing and operating retail cannabis dispensaries in Puerto Rico and California. The company is currently in the process of increasing its stake in GSRX Industries to 66.29 percent in order to become a fully vertically-integrated, multistate operator with assets in six states: California, Tennessee, Arizona, Michigan, Texas and Puerto Rico.

In addition to California and Puerto Rico, Chemesis International is working towards opening exclusively branded retail locations in multiple cannabis markets across the globe. To this aim, the company has acquired La Finca Interacviva-Arachna Med, a licensed cannabis company in Colombia with strategic relationships across the agricultural and educational industries. Chemesis International also provides consumers with a variety of extracts, formulations and products.

Chemesis International recently closed $25 million in equity financing with Alumina Partners, LLC. Under the agreement with the private equity firm, the company intends to continue its growth strategy with financial flexibility and freedom, with the ability to access the available funds at their discretion.

Chemesis International’s management, insiders and strategic shareholders notably own 75 percent of the company shares. Management owns 14 percent of the shares in the company.

Chemesis Highlights

  • First mover in Puerto Rico’s recently legalized and growing medical cannabis market.
  • Selling cannabis products in approximately seven locations across Puerto Rico.
  • Received awards for best topical, tincture and vaporizer in Puerto Rico.
  • Access to Latin American cannabis market through Chemesis Latin America subsidiary.
  • Expected annual revenue of $6.7 million by year four with a net income of $2.8 million in Puerto Rico.
  • Secured up to US$10 million in annual purchase agreements in Puerto Rico.
  • Developing a presence in California’s legalized medical and adult-use cannabis market.
  • Expected annual revenue of US$61.5 million by year four with a net income of $27.2 million in California.
  • Exclusive agreement with California Sap.
  • Binding agreements for distribution and sale of tested cannabis oil.
  • Strategic agreement with Kevin Smith and Jason Mewes.
  • Made US$100,000 in purchase orders after launch of the Jay and Silent Bob brand.
  • Strategic partnership in place with Dank City.
  • Interest in GSRX Industries furthers Chemesis International’s retail strategy in the US and Puerto Rico.
  • $25 million equity financing with Alumina Partners.
  • Management, insiders and significant shareholders notably hold 75 percent of the company shares.

Chemesis International’s Vertically-Integrated Business Model

Chemesis International is currently operating in Puerto Rico, Colombia and California with a seed-to-sale model.

Cultivation

In addition to the Cathedral City facilities, Chemesis International has holdings in Puerto Rico, including a state-of-the-art grow facility, which will have a production capacity of 30,000 pounds per year. The company has partnered with VividGro, a leader in agricultural technology for consumer and commercial applications. Under the terms of the agreement, VividGro is expected to provide its latest generation of LED lighting systems and environmental controls to the facility as well as support as Chemesis International builds out its facilities.

Having acquired 80 percent of Natural Ventures in Puerto Rico, the company now also has access to a licensed 100,000-square-feet of cannabis cultivation space. Chemesis has also acquired La Finca Interacviva-Arachna Med, an integrated, licensed cannabis company that has been operational in the country since October 2017, and has access to over 1,000 acres of land for outdoor cultivation purposes.

Currently, Chemesis International is looking at expansion opportunities that are under review in both Puerto Rico and California.

Manufacturing

Chemesis International is a specialist in extraction techniques and has invested in equipment for alcohol, BHO and CO2 extraction. The CO2 extraction process used to develop the California Sap brand results in highly-concentrated cannabis oil made up of 89 percent cannabinoids.

Chemesis International has also signed a definitive agreement to acquire a fully-operational extraction and manufacturing facility in Cathedral City, California to expand the company’s processing ability to over 500,000 kilograms of cannabis annually. The facility utilizes a volatile butane hash oil extraction method that allows for the rapid and efficient extraction of cannabinoids from trim which is expected to expand the company’s ability to provide THC and CBD products.

California Sap’s Gramqul product is a new form of packaging for cannabis oil. It is a versatile product that allows users to choose the best way to consume cannabis. The company’s vape cartridges, meanwhile, have a standard 510 threading and are compatible with most batteries. They include an airflow control valve that can be adjusted according to the consumer’s preferences.

With the goal of expanding its manufacturing presence in the US, Chemesis International has entered a binding agreement to acquire a fully-operational cannabis manufacturing facility in Arizona, establishing the company as a multi-state operator. The 5,000-square-foot facility comes with a team of operators in place and generated approximately US$1 million in revenue in Q1 2019. The facility currently produces finished goods such as hard and soft capsules, cartridges, lotions, tinctures and other liquid formulations.

In Puerto Rico, Natural Ventures has 35,000 square feet of manufacturing floor space, currently producing solvent and CO2-based extraction for its oil-based products. It also has the capacity to produce edibles and other cannabis products.

In February 2019, Chemesis International acquired the intellectual property (IP) and equipment needed to preserve all the phytocannabinoids and terpenes from cannabis utilizing a low-temperature process to create live resin. The process allows the company to produce a variety of finished goods such as tinctures, shatters, vapes and oils, among others.

In August 2019, Chemesis International commenced the manufacturing, packaging and distribution of its tobacco-free smokeless cannabis and hemp-derived chew. The company plans to initially launch and commercialize the new product in the US, Canada and Puerto Rico. The chew is non-psychoactive and will be available in multiple flavors and is expected to provide a healthier alternative to the tobacco chews currently available. So far, Chemesis International has signed 34 LOIs with privately-owned liquor stores in British Columbia for the distribution of its hemp-based chew products.

Distribution

Chemesis has established relationships with distributors around the globe. Chemesis is able to serve Puerto Ricans across the island from seed-to-sale.

In line with new regulations set forth in January in California, Chemesis has emerged as a compliant first mover in distribution in the state. To this effect, Chemesis has entered into a binding supply agreement with a distribution company that delivers premium, lab-tested cannabis product to dispensaries and licensed producers in the state. Known for high compliance standards, the vendor has the capability to test cannabis for potency, moisture, terpenes and pesticides. As part of the agreement, the vendor is expected to provide Chemesis with 10,000 pounds of clean tested trim per month, supplying the company’s production of California Sap and other white labeled products.

“This is a critical achievement that positions the company for significant growth in the California market, particularly with recent regulation changes restricting many in the California market. The company is confident this agreement will build a strong revenue stream while continuing to build an efficient and streamlined manufacturing facility in Cathedral City. Chemesis will continue to build value by maintaining cost efficiency and ensuring we are supplying the market with high-quality oils,” said Edgar Montero CEO of Chemesis.

Retail

Chemesis has developed a retail presence in Puerto Rico and is entering the retail space in California. Chemesis is also planning on opening exclusively-branded retail locations across the globe.

To this aim, Chemesis International has acquired a 19.9 percent interest in GSRX Industries, a company in the business of acquiring, developing and operating retail cannabis dispensaries in Puerto Rico and California. Chemesis International is currently in the process of increasing its stake in GSRX Industries to 66.29 percent in order to become a fully vertically-integrated, multistate operator with assets in six states: California, Tennessee, Arizona, Michigan, Texas and Puerto Rico.

Chemesis International’s Target Markets

California

California has a total population of nearly 40 million and a medical cannabis market that includes roughly one million patients. In 2016, California’s licensed medical market was worth an estimated $2.81 billion. As of January 1, 2018, California legalized adult-use cannabis, making it one of the largest recreational cannabis market in the world. Following legalization, California’s cannabis market hit a total of $2.5 billion in 2018 and is expected to reach $50 billion by 2026. With these promising market projections, Chemesis International has secured market share in the world’s largest recreational cannabis market.

Puerto Rico

In May 2015, Puerto Rico’s Governor Alejandro García Padilla signed an executive order that legalized the use of medical cannabis. The Puerto Rican Health Department has reported that there are tens of thousands of patients registered at the Puerto Rico Medical Cannabis Association (PRMCA) who are being treated for a variety of debilitating diseases including epilepsy, Parkinson’s disease, multiple sclerosis, anxiety disorder, fibromyalgia, arthritis and cancer. Additionally, the PRMCA estimates that the cannabis industry has generated more than $35 million and has created more than 1,000 direct and indirect jobs.

In July 2017, Governor Ricardo Rosselló signed a law that regulates and formally legalizes the use of medicinal cannabis on the island. After the legalization of medicinal cannabis in Puerto Rico, Chemesis International entered the market as a first-mover and expects annual revenue of $6.7 million by year four, with a net income of $2.8 million from operations in the region.

Colombia

Colombia has a population of 48.8 million and is home to 6 million potential cannabis patients. The country’s population, among other factors, has positioned it as a leader in the global cannabis industry. It is estimated that the country can supply up to 44 percent of the global demand for cannabis. Colombia also offers low operating costs, unique strains and a climate that supports year-round cultivation.

Chemesis Latin America

In September 2018, Chemesis International announced the opening of its wholly-owned subsidiary, Chemesis Latin America. The subsidiary will be responsible for exploring and evaluating opportunities for production, cultivation and export of cannabis across the region.

The company plans to capitalize on the positive shift of Latin America’s market, which recently saw the Mexican Supreme Court recommend the decriminalization of cannabis. Colombia also hosts a growing market, with the government expecting to see up to 40.5 tons of cannabis produced annually, capturing as much as one-fifth of the global market.

“Chemesis Latin America is a big step forward in our global growth strategy,” said Chemesis International CEO Edgar Montero. “We believe Chemesis has a major advantage in this region, as the recent acquisition of Natural Ventures can be leveraged to quickly capitalize on upcoming opportunities. With progressive regulations, Latin America becomes a key market that will be a major part of our portfolio. Chemesis has positioned itself to take advantage of significant opportunities in both Mexico and Colombia. This allows Chemesis to execute on its ambitious growth strategy to identify opportunities that will build long-term shareholder value.”

Michigan

As part of its expansion strategy, Chemesis International entered the Michigan cannabis market when it received its hemp cultivation and processing licenses. The company is in the process of planting its first 13 acres of hemp. The acquisition was quickly followed by the company gaining state approval to commence construction on its hemp processing facility.

According to projections by Marijuana Business Daily, the Michigan cannabis market could reach as high as US$1.7 billion in annual revenue within the first few years after legalization, making it one of the largest cannabis markets in the US. The state is also home to the country’s second highest number of registered medical users.

Chemesis International’s Acquisitions

Natural Ventures

Chemesis International has an 80 percent holding of Natural Ventures, a licensed cultivator, manufacturer and distributor of cannabis products. Headquartered in Puerto Rico, the company has strategic partnerships with a number of leading brands in the cannabis industry that span across numerous countries.

Following the passing of the US Farm Bill, Natural Ventures entered Puerto Rico’s CBD market and launched a beverage division in January 2019. The company intends to produce all-natural ingredient products such as an energy shot, a sleep shot and a calming shot.

Natural Ventures has also entered into a licensing agreement to produce Dragonglass Flake and Bake for a subsidiary of GSRX Industries and will be available exclusively at Green Spirit RX dispensaries throughout Puerto Rico. Dragonglass is made using a proprietary technology that allows users to consume cannabis in a variety of methods, flavors and colors.

The following month, Natural Ventures signed a definitive agreement for a US$4 million annual purchase agreement for a Puerto Rico-based dispensary network. Natural Ventures is expected to provide the vendor with edibles, vaporizers, lotions, beverages and flower that is cultivated, packaged and distributed from its fully-licensed and fully-compliant facility.

Natural Ventures has also signed a US$6 million purchase agreement with PR ONE, a Puerto Rico-based medical cannabis company. The three-year agreement has options for renewal and PR ONE has committed to purchasing a minimum of US$300,000 per month in cannabis-infused products and US$200,000 in flower. Natural Ventures is also expected to be PR ONE’s main manufacturer.

SAP Global 

SAP Global is a state-of-the-art production facility located strategically in Cathedral City, California. The Company manufactures and distributes recreational cannabis products for the California market. The facility and its operations are fully compliant with all California regulations.

California Sap

California Sap is known for its experience, purity and products. The company has also been recognized with multiple awards across California and Nevada for a variety of factors. It offers two main cannabis accessory products to consumers and has won multiple awards over the 15 years they have been in operation.

In July 2018, Chemesis International entered into two binding agreements with for sale and distribution of California Sap products. The agreements cover the distribution of 100 liters of tested cannabis oil per month and allow the company to significantly increase its distribution and sale networks.

Desert Zen

Acquired by Chemesis International in August 2018, Desert Zen is a recreational and medicinal cannabis manufacturing, distribution and transportation company based in California. The company is licensed under state and local laws to manufacture, package, distribute and transport cannabis product across its large existing network. The company has the ability to track products, monitoring them for safety and ensuring that they abide by all seed-to-sale laws across the supply chain.

La Finca Interacviva-Arachna Med

In January 2019, Chemesis International completed its acquisition of Colombia-based La Finca Interacviva-Arachna Med. La Finca is an integrated, licensed cannabis company that has been operational in the country since October 2017, and has access to over 1,000 acres of land for outdoor cultivation purposes. It is also a founding member of the Association for the Promotion of Hemp Growing, which is a non-profit organization focused on cannabis education and providing technical advice for cultivation. La Finca is a strategic acquisition as it has relationships with over 2,000 farming families across Colombia through various co-ops.

The company has a number of manufacturing relationships as well as C$2.3 million in working capital that could be used for the expansion of its operations. La Finca’s licensed cosmetic products are certified under the organization equivalent to the US FDA, the Instituto Nacional de Vigilancia de Medicamento (INVIMA).

La Finca has also developed an R&D presence through partnerships with the Universidad Nacional de Colombia. Together, the two parties intend to develop seed strains that shorten crop cycles while increasing biomass and flower yield. The company is also partnered with the Universidad Distrital Francisco José de Caldas, building an educational program on cannabis cultivation.

Chemesis International commenced construction on its GMP-certified extraction facility in Bogota, Columbia. The state-of-the-art facility is expected to house a certified production lab which will be able to create products for the domestic and international markets. La Finca received its seed producers license in January and is now able to export its high-concentrate CBD genetics, distillates and other manufactured products. The company received three additional cultivation licenses in May 2019, which are expected to cover any expansions of La Finca’s property.

Viverian

In December 2018, Chemesis International acquired Viverian, a hemp-derived CBD product line that promotes healthy living and provides consumers with quick and easy consumption methods. The brand is available through an online e-commerce platform with distribution in Arizona, Nevada and Florida.

The Viverian product line includes CBD tinctures as well as capsules that may assist with sleep, relaxation, improved concentration, discomfort relief and improved health and wellness. Since acquiring the brand, Chemesis International has expanded it into a retail strategy. The company will roll the brand out in additional states as regulations are established for CBD manufacturing and distribution. Chemesis International officially launched the brand in Puerto Rico in April 2019.

“Natural Ventures is a key part of Chemesis’ long-term strategy to build a major presence in Latin America, and by launching Viverian, it allows penetration into the Puerto Rican CBD market,” said Montero. “Chemesis believes it has an advantage in the Latin American CBD market as it is able to leverage its state-of-the-art facility, its previously announced partnership with First Medical that brings up to 6,000 acres of hemp cultivation, and its all-natural Viverian CBD product catalog.”

GSRX Industries

In April 2019, Chemesis International acquired a 19.9 percent interest in GSRX Industries, a company in the business of acquiring, developing and operating retail cannabis dispensaries in Puerto Rico and California. Chemesis International is now in the process of acquiring a 66.29 percent interest in GSRX Industries in order to become a fully vertically-integrated, multistate operator with assets in six states: California, Tennessee, Arizona, Michigan, Texas and Puerto Rico. The deal is expected to bring in a projected US$75 million in 2020.

GSRX Industries owns five operational dispensaries in Puerto Rico that operate under the Green Spirit Rx brand and have pre-qualified for an additional five dispensaries. The company also owns a fully-licensed cannabis distribution center in Point Arena, California that is expected to service over 400 dispensaries in northern and central California.

GSRX Industries also owns the Green Room dispensary in Point Arena. The company also owns an additional 4,500-square-foot Green Room location in Palm Springs that is currently undergoing renovations. GSRX Industries also owns retail locations in Texas and Tennessee.

California Manufacturing Facility

Chemesis International has also signed a definitive agreement to acquire a fully-operational extraction and manufacturing facility in Cathedral City, California to expand the company’s processing ability to over 500,000 kilograms of cannabis annually. The facility utilizes a volatile butane hash oil extraction method that allows for the rapid and efficient extraction of cannabinoids from trim which will expand the company’s ability to provide THC and CBD products.

Chemesis International’s Partnerships

Kevin Smith and Jason Mewes

Chemesis International has entered into a multi-year licensing agreement with Kevin Smith and Jason Mewes, also known as Jay and Silent Bob. The agreement covers the development and promotion of cannabis products in the US market, specifically flowers, oils, extracts, pre-rolls, edibles and more. Smith and his character, Jay, have a collective social media footprint of 12.4 million followers, as well as additional ongoing projects that amount to increased social reach.

Chemesis International officially launched the Jay and Silent Bob brand in December 2018. Within its first week of sales, the brand brought in over US$100,000 in purchase orders.

“We are extremely pleased with the progress that the Jay & Silent Bob brand has made in such a short period of time,” said Montero. “The team received a very positive reception at Emerald Cup, not only generating significant interest in the brand, but also showed the ability to secure significant purchase orders in just the first week of its launch. To assist with further growth, Chemesis will leverage its existing distribution relationships to bring the brand to dispensaries in southern California.”

Julian Marley Juju Royal™ brand

Chemesis International has a fulfillment and distribution agreement for the Julian Marley Juju Royal™ brand, which consists of high-quality cannabis products. The products will be packaged, fulfilled and distributed from Chemesis’ Desert Zen facility and will cover Juju Royal’s™ Southern California operations.

“The agreement for JuJu Royal is another example of Chemesis’ ability to deliver consistent quality products, validating Management’s business plan and growth strategy,” said Montero. “Brands that require high-quality services are recognizing our ability to consistently handle full compliance capacity for all of their high-quality products. As Chemesis gains more exposure in the market place, we anticipate the need for quality reliable services to continue to rise. Agreements such as this will ensure we are able to build stable, long term value for the Company.”

Rapid Dose Therapeutics

Chemesis International and Rapid Dose Therapeutics, a Canadian biotechnology company developing proprietary drug delivery technologies, have signed a definitive agreement which enables Chemesis to produce Rapid Dose’s QuickStrips™ with infused cannabis oils. QuickStrip is an oral, fast-dissolving drug delivery system that Rapid Dose developed with McMaster University.

As part of the initial agreement, Chemesis International has the rights to produce, distribute and sell QuickStrip products in California. The companies have also signed a subsequent agreement under which Chemesis is expected to produce, distribute and sell QuickStrip™ oral thin strips in Puerto Rico.

“We are pleased to bring RDT and their QuickStrip™ oral thin strips to another growing cannabis market, and we believe this will allow the company to further increase its market position in Puerto Rico,” said Montero. “With RDT recently announcing Aphria as a partner in select global markets, we feel our partnership will add tremendous value to our shareholders.”

Chemesis International began commercialization of QuickStrips™ in June 2019. The company intends to manufacture and distribute the oral thin strips through Natural Ventures’ facility in Puerto Rico.

As the company expands its manufacturing business, Chemesis International has been looking to expand its presence in the US. The company’s recent move into Michigan sparked another definitive agreement with Rapid Dose to bring its QuickStrips™ into the state. Under the agreement, Chemesis retains the option to add future markets as opportunities arise.

Dank City

Chemesis International and Dank City, a social media marketing company specializing in cannabis products and brands, have formed a strategic partnership where Dank City will advertise for the Jay and Silent Bob’s Private Stash product line as well as other product brands. Under the terms of the agreement, Dank City will provide a year’s worth of advertising services to Chemesis International.

Dank City owns and operates the largest cannabis social media network and reaches over 100 million followers across its social media platforms. The company also offers a subscription box that reaches 15,000 customers monthly, a cannabis magazine and a platform for cannabis content creators.

“Chemesis believes this partnership with Dank City and their worldwide reach will not only generate significant interest in Jay and Silent Bob’s Private Stash, but Chemesis’s other affiliated brands,” said Montero. “Dank City has built a media firm that has the ability to effectively target the US cannabis consumer base. As Chemesis continues its growth, this vital partnership will allow the company to quickly reach cannabis consumers with our expanding product catalog.”

First Medical Cannabis

Chemesis International has partnered with First Medical to cultivate hemp with high yields of CBD in Puerto Rico. Initially, Chemesis International is expected to have access to 1,000 acres for hemp cultivation and has the option to expand up to 5,000 acres. Chemesis International plans to leverage its fully-compliant facility to manufacture, process and distribute hemp-derived CBD products. The facility is expected to offtake all hemp produced by First Medical and process it into finished goods for the domestic and international markets.

Happy Tea

Chemesis International has partnered with Happy Tea, a US-based brand that offers CBD-infused sachets and shots. The partnership is expected to allow Happy to expand its product offering and realize cost savings by leveraging Chemesis International’s extraction, manufacturing and retail distribution services.

Happy Tea currently offers three products that are comprised of blends of all-natural ingredients, antioxidants and 10 milligrams of CBD. The products can be purchase individually or as a monthly subscription and are shipped through the company’s e-commerce sales channels across the US.

Chemesis International has agreed to help Happy Tea expand its three SKUs to nine and manufacture Happy Tea’s products in its US-based facilities. As per the partnership, Chemesis International expects to receive a US$4 million minimum purchase order from Happy Tea.


*Disclaimer: The profile provides information which was sourced and approved by Chemesis International in order to help investors learn more about the company. Chemesis International  is a client of the Investing News Network (INN). The company’s campaign fees pay for INN to create and update this profile page, to which links are placed on Investingnews.com and channel newsletters.

The company description, investment highlights and catalysts were sourced by INN and approved by the company. INN does not guarantee the accuracy or thoroughness of the information contained on this page.

INN does not provide investment advice and the information on Investingnews.com profile should not be considered a recommendation to buy or sell any security.

INN does not endorse or recommend the business, products, services or securities of any company profiled.

Readers should conduct their own research for all information publicly available concerning the company.